TrianglePUBLICATIONS · 28520840
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Ann Oncol
- Publication date
- 2017 Aug 1
- First author
- Zhao X
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Zhao X
- type
- Author
- name
- Suryawanshi S
- type
- Author
- name
- Hruska M
- type
- Author
- name
- Feng Y
- type
- Author
- name
- Wang X
- type
- Author
- name
- Shen J
- type
- Author
- name
- Vezina HE
- type
- Author
- name
- McHenry MB
- type
- Author
- name
- Waxman IM
- type
- Author
- name
- Achanta A
- type
- Author
- name
- Bello A
- type
- Author
- name
- Roy A
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Zhao X
- type
- Author
- name
- Suryawanshi S
- type
- Author
- name
- Hruska M
- type
- Author
- name
- Feng Y
- type
- Author
- name
- Wang X
- type
- Author
- name
- Shen J
- type
- Author
- name
- Vezina HE
- type
- Author
- name
- McHenry MB
- type
- Author
- name
- Waxman IM
- type
- Author
- name
- Achanta A
- type
- Author
- name
- Bello A
- type
- Author
- name
- Roy A
- type
- Author
- bibliography ids
- nci-bib-3a6632f231ef40e7d67ea642
- book metadata
- content sha256
- c704bfdb5a9fff4d730686e00c45dc1c6302cce6fd53c4bc6a471cb2d101d38e
- document type
- citation
- dois
- 10.1093/annonc/mdx235
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:28520840
- immutable id
- pubmed:28520840@c704bfdb5a9fff4d730686e00c45dc1c6302cce6fd53c4bc6a471cb2d101d38e
- journal
- abbreviation
- Ann Oncol
- issn electronic
- 1569-8041
- issn print
- 0923-7534
- issue
- 8
- name
- Annals of oncology : official journal of the European Society for Medical Oncology
- nlm unique id
- 9007735
- pages
- 2002-2008
- volume
- 28
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 28520840
- provenance
- batch id
- 1c173f0e18be0c6d461b
- provider
- NCBI PubMed ESummary
- record sha256
- 0ddf7d3ade50bb4a0b63514e33e8048a30463a4d3baed1122c3422ebac137e92
- response sha256
- 27a6f8bb5d49a8d376b07e1b1768913c558986bf73de92cdd65c8f05a5fa1e61
- retrieved at
- 2026-09-09T23:47:25.975513+00:00
- publication date
- display
- 2017 Aug 1
- precision
- day
- year
- 2017
- publication types
- Journal Article
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.
Preserved source evidence · Not medical advice